Health Net Named Among America’s Top LGBTQ+ Workplaces 2024 by Newsweek
Health Net, a prominent Medi-Cal managed care health plan in California and part of Centene Corporation, announced today its recognition as one of “America’s Greatest Workplaces for LGBTQ+ 2024” by Newsweek and Plant-A Insights Group. This accolade follows a survey…
Opening of WellCare Welcome Room in Raleigh: Healthcare Resources and Community Support
WellCare of North Carolina (WellCare), the Medicaid subsidiary of Centene Corporation (NYSE: CNC), unveiled a new WellCare Welcome Room in Raleigh today. This facility serves as a dedicated space where members can learn about health plans, explore benefits, engage with…
Global Diabetes & Obesity Therapeutics 2024-2028: Lucrative GLP-1-based Multi-agonist Market
The “Growth Opportunities in Global Diabetes and Obesity Therapeutics, 2024-2028” report has been recently included in ResearchAndMarkets.com’s offerings. This comprehensive study aims to identify key growth opportunities driving the diabesity market in the coming years. It focuses on emerging business…
Timothy Hatch Receives Walter F. Snyder Environmental Health Award
NSF and the National Environmental Health Association (NEHA) have jointly announced Timothy Hatch, MPA, REHS, as the recipient of the 2024 Walter F. Snyder Environmental Health Award. This prestigious accolade honors Hatch for his exceptional contributions to advancing environmental and…
Novo Integrated Sciences Q3 FY 2024 Financial Results
Novo Integrated Sciences, Inc. (NASDAQ: NVOS), a pioneer in patient-centric health and wellness solutions through an integrated healthcare ecosystem, today announced its financial results for the third fiscal quarter ending May 31, 2024. Robert Mattacchione, CEO and Board Chairman of…
GRO Biosciences Raises $60M in Series B Financing
GRO Biosciences Inc. (“GRObio”), a pioneering biotechnology firm utilizing synthetic biology to enhance the amino acid repertoire and advance protein therapeutics, has successfully concluded an oversubscribed Series B financing round, raising $60.3 million. This funding milestone marks a significant step…
RefleXion Presents 37 Research Studies at AAPM 2024
RefleXion Medical, a leader in external-beam theranostic oncology, has announced that researchers will present pioneering scientific findings in 37 oral and poster presentations at the 2024 American Association of Physicists in Medicine (AAPM) Annual Meeting in Los Angeles, July 21-25.…
Blood Filtration: Hope Against Pancreatic Cancer
Researchers have made a groundbreaking advance in cancer treatment by successfully using Seraph® 100 blood filtration media to remove Circulating Tumor Cells (CTCs) from patients with advanced pancreatic cancer. This breakthrough supports ExThera Medical’s ONCObind™ Procedure Hemoperfusion Filter (ONCObind™), designed…
Canadian Healthcare Provider Chooses Crescita as Exclusive Partner
Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF), a Canadian commercial dermatology company focused on growth and innovation, has announced the signing of an exclusive Manufacturing and Supply Agreement with a leading Canadian diversified healthcare services provider. This agreement…
Ora Secures Vistria Group Investment for Global Growth in Ophthalmic Research
Ora, a leading global contract research organization (CRO) specializing in ophthalmic research, has announced a strategic recapitalization by The Vistria Group, a middle-market private investment firm focused on delivering financial returns and societal impact. “The Vistria Group’s investment underscores their…
Novo Integrated Sciences Receives Notice to Commence SBLC Leasing and Monetizing Program
Novo Integrated Sciences, Inc. (NASDAQ: NVOS) announced today the initiation of disbursement for the full monetization of a Standby Letter of Credit (“SBLC”). This initial disbursement marks the first payment under the arrangement, leading to a release of lien and…
Opdivo plus Yervoy Application Validated by EMA for Liver Cancer
Bristol Myers Squibb (NYSE: BMY) has announced that the European Medicines Agency (EMA) has validated its Type II variation application for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a potential first-line treatment for adults with unresectable or advanced hepatocellular carcinoma (HCC)…